Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peg-Intron and Thalidomide in Recurrent High-Grade Gliomas
NCT00047879Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Oct 2002
- Primary completion
- Jun 2009
- Modality
- Polymer-based Nanoparticles, Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of peginterferon alfa-2b in malignant glioma, sponsored by National Cancer Institute. Started Oct 2002; status: completed.
02
Drugs
peginterferon alfa-2b
03
Conditions
malignant glioma
Beyond the preview
Go deeper on NCT00047879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00047879.